• 1
    Greenberg A, Thompson M, Griffith B et al. Cyclosporine nephrotoxicity in cardiac allograft patients—a seven year follow-up. Transplantation 1990; 50: 589593.
  • 2
    Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC, Theodore J. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995; 26: 643648.
  • 3
    Broekroelofs J, Stegeman CA, Navis G, De Jong PE. Prevention of renal function loss after non-renal solid organ transplantation—how can nephrologists help to keep the kidneys out of the line of fire? Nephrol Dial Transplant 1999; 14: 18411843.
  • 4
    Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999; 10: 11361144.
  • 5
    Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61: 22282234.
  • 6
    Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931940.
  • 7
    Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 1997; 63: 664668.
  • 8
    Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699705.
  • 9
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39(2 Suppl 2): S1246.
  • 10
    Lanese D, Conger J. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91: 21442149.
  • 11
    Ruggenenti P, Perico N, Mosconi L et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706711.
  • 12
    Scherrer U, Vissing SF, Morgan BJ et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693699.
  • 13
    Zaltzman JS, Pei Y, Maurer J, Patterson A, Cattran DC. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 1992; 54: 875878.
  • 14
    Sehgal V, Radhakrishnan J, Appel GB, Valeri A, Cohen DJ. Progressive renal insufficiency following cardiac transplantation: Cyclosporine, lipids, and hypertension. Am J Kidney Dis 1995; 26: 193201.
  • 15
    Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 1997; 11: 18.
  • 16
    Broekroelofs J, Navis GJ, Stegeman CA et al. Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss. Transplantation 2000; 69: 16241628.
  • 17
    Vossler MR, Ni H, Toy W, Hershberger RE. Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation. J Heart Lung Transplant 2002; 21: 874881.
  • 18
    Myers B, Newton L. Cyclosporine-Induced chronic nephropathy: an obliterative microvascular renal injury. J Amer Soc Nephrol 1991; 2: S45S52.
  • 19
    Gardner M, Houghton D, Andoh T, Lindsley J, Bennett W. Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition. Transplantation 1996; 61: 15061512.
  • 20
    Binet I, Wallnofer A, Weber C, Jones R, Thiel G. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int 2000; 57: 224231.
  • 21
    Israni A, Brozena S, Pankewycz O, Grossman R, Bloom R. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kidney Dis 2002; 39: E16–20.
  • 22
    Klein IH, Abrahams A, Van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732736.
  • 23
    Pratschke J, Neuhaus R, Tullius S et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997; 64: 938940.
  • 24
    English RF, Pophal SA, Bacanu SA et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. Am J Transplant 2002; 2: 769773.
  • 25
    Shihab FS. Cyclosporine nephropathy: Pathophysiology and clinical impact. Semin Nephrol 1996; 16: 536547.
  • 26
    Bertani T, Ferrazzi P, Schieppati A et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40: 243250.
  • 27
    Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62: 364370.
  • 28
    Griffiths MH, Crowe AV, Papadaki L et al. Cyclosporin nephrotoxicity in heart and lung transplant patients. Qjm 1996; 89: 751763.
  • 29
    Langham RG, Egan MK, Dowling JP, Gilbert RE, Thomson NM. Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 2001; 72: 18261829.
  • 30
    Jain S, Mohamed MA, Sandford R, Furness PN, Nicholson ML, Talbot D. Sequential protocol biopsies from renal transplant recipients show an increasing expression of active TGF beta. Transpl Int 2002; 15: 630634.
  • 31
    Trimarchi HM, Truong LD, Brennan S, Gonzalez JM, Suki WN. FK506-associated thrombotic microangiopathy: Report of two cases and review of the literature. Transplantation 1999; 67: 539544.
  • 32
    Roberts P, Follette D, Allen R, Katznelson S, Albertson T. Cyclosporine A-associated thrombotic thrombocytopenic purpura following lung transplantation. Transplant Proc 1998; 30: 15121513.
  • 33
    Barone GW, Gurley BJ, Abul-Ezz SR, Gokden N. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003; 42: 202206.
  • 34
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 12961305.
  • 35
    Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 12851295.
  • 36
    Ventura HO, Mehra MR, Stapleton DD, Smart FW. Cyclosporine-induced hypertension in cardiac transplantation. Med Clin North Am 1997; 81: 13471357.
  • 37
    Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336345.
  • 38
    Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754762.
  • 39
    Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001; 59: 260269.
  • 40
    End A, Stift A, Wieselthaler G et al. Anemia and erythropoietin levels in lung transplant recipients. Transplantation 1995; 60: 12451251.
  • 41
    Frost AE, Keller CA. Anemia and erythropoietin levels in recipients of solid organ transplants. The Multi-Organ Transplant Group. Transplantation 1993; 56: 10081011.
  • 42
    Hunt BJ, Amin S, Halil O, Yacoub M. The prevalence, course, and characteristics of chronic anemia after heart and lung transplantation. Transplantation 1992; 53: 12511256.
  • 43
    Gleissner CA, Murat A, Schafer S et al. Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation 2004; 77: 710717.
  • 44
    Dubrey SW, Holt DW, Banner N. Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels. Ther Drug Monit 1999; 21: 325326.
  • 45
    Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20: 345349.
  • 46
    Tepel M, Van Der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180184.
  • 47
    Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291: 23282334.
  • 48
    Canver CC, Heisey DM, Nichols RD. Acute renal failure requiring hemodialysis immediately after heart transplantation portends a poor outcome. J Cardiovasc Surg (Torino) 2000; 41: 203206.
  • 49
    Snell GI, Levvey BJ, Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540546.
  • 50
    Zakliczynski M, Nozynski J, Zakliczynska H, Rozentryt P, Zembala M. Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc 2003; 35: 23312332.
  • 51
    Trosch F, Rothenburger M, Schneider M et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004; 52: 163168.
  • 52
    Groetzner J, Meiser B, Landwehr P et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568574.
  • 53
    Groetzner J, Kaczmarek I, Landwehr P et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 2004; 25: 333341.
  • 54
    De Meester JM, Van Vlem B, Walravens M et al. Preservation of renal function after heart transplantation: Initial single-center experience with sirolimus. Transplant Proc 2005; 37: 18351838.
  • 55
    Zucker MJ, Baran DA, Arroyo LH et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: A one-year follow-up analysis. Transplant Proc 2005; 37: 22312239.
  • 56
    Aleksic I, Baryalei M, Busch T et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000; 69: 15861590.
  • 57
    Tedoriya T, Keogh AM, Kusano K et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002; 21: 976982.
  • 58
    Bunke M, Ganzel B. Effect of calcium channel antagonists on renal function in hypertensive heart transplant recipients. J Heart Lung Transplant 1992; 11: 11941199.
  • 59
    Brozena SC, Johnson MR, Ventura H et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail. J Am Coll Cardiol 1996; 27: 17071712.
  • 60
    Elliott WJ, Murphy MB, Karp R. Long-term preservation of renal function in hypertensive heart transplant recipients treated with enalapril and a diuretic. J Heart Lung Transplant 1991; 10: 373379.
  • 61
    Lin J, Valeri AM, Markowitz GS, D'Agati VD, Cohen DJ, Radhakrishnan J. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73: 783788.
  • 62
    Hetzel GR, Hermsen D, Hohlfeld T et al. Effects of candesartan and perindopril on renal function, TGF-beta1 plasma levels and excretion of prostaglandins in stable renal allograft recipients. Clin Nephrol 2002; 57: 296302.
  • 63
    Braith RW, Mills RM, Wilcox CS, Mitchell MJ, Hill JA, Wood CE. High dose angiotensin-converting enzyme inhibition prevents fluid volume expansion in heart transplant recipients. J Am Coll Cardiol 2000; 36: 487492.
  • 64
    Schwietzer GK, Hartmann A, Kober G et al. Chronic angiotensin-converting enzyme inhibition may improve sodium excretion in cardiac transplant hypertension. Transplantation 1995; 59: 9991004.
  • 65
    Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998; 66: 268271.
  • 66
    Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 25602572.
  • 67
    American Heart Association, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 31433421.
  • 68
    Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621627.
  • 69
    Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? Pharmacol Ther 1998; 80: 134.
  • 70
    Kasiske B, Cosio FG, Beto J et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4(Suppl 7): 1353.
  • 71
    Lemahieu WP, Hermann M, Asberg A et al. Combined therapy with atorvastatin and calcineurin inhibitors: No interactions with tacrolimus. Am J Transplant 2005; 5: 22362243.
  • 72
    Devuyst O, Goffin E, Pirson Y, Van Ypersele de Strihou C. Creatinine rise after fibrate therapy in renal graft recipients. Lancet 1993; 341: 840.
  • 73
    Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001; 55: 3944.
  • 74
    Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005; 37: 10331035.
  • 75
    Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005; 39: 15611565.
  • 76
    Anand IS, Kuskowski MA, Rector TS et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112: 11211127.
  • 77
    National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001: 37(1 Suppl 1): S182238.
  • 78
    Meier-Kriesche HU, Port FK, Ojo AO et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 13111317.
  • 79
    Mange K, Marshall J, Feldman H. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 8: 726731.
  • 80
    Bernardini J, Piraino B, Kormos RL. Patient survival with renal replacement therapy in heart transplantation patients. ASAIO J 1998; 44: M546548.
  • 81
    Frimat L, Villemot JP, Cormier L et al. Treatment of end-stage renal failure after heart transplantation. Nephrol Dial Transplant 1998; 13: 29052908.